RxDoctor Payments Data

Noreen Iqbal, MD

Family Medicine · Mansfield, MANPI 1386808210

Payments from drug & device makers

$483in general payments, 2019–2025

Across 15 payments — averaging $32.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cequr Corporation$144
  • Boehringer Ingelheim$45
  • Exact Sciences$44
  • AstraZeneca$43
  • Johnson & Johnson$34
  • Novo Nordisk$32
  • plus $139 from 6 others

What the payments were for

  • Food & beverage$483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$483 in reported general payments places this provider in the 75th percentile of 1,049 family medicine providers in Massachusetts.

See all family medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$77,385
Medicare patients
209
Services billed
728

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin43$69,481
TrulicityDulaglutide47$57,726
EliquisApixaban46$54,806
JanuviaSitagliptin Phosphate28$38,837
Combivent RespimatIpratropium/Albuterol Sulfate12$7,203
Incruse ElliptaUmeclidinium Bromide12$6,709
Atorvastatin Calcium379$4,790
Omeprazole245$3,916
Albuterol Sulfate HfaAlbuterol Sulfate104$3,247
Lantus SolostarInsulin Glargine,hum.Rec.Anlog28$3,210
Metoprolol Succinate163$3,127
Rosuvastatin Calcium60$2,704
Lisinopril310$2,424
Duloxetine Hcl35$2,186
Ezetimibe49$2,029

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$45$76,68455 claims
PfizerEliquis$28$54,80646 claims
GSKIncruse Ellipta$24$6,70912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,049 family medicine providers in Massachusetts.

Other family medicine in Mansfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →